ACADIA Pharmaceuticals Inc
Latest ACADIA Pharmaceuticals Inc News and Updates
Alnylam Pharmaceuticals Initiates Phase 1 Trial of ALN-TTRsc02
Alnylam Pharmaceuticals (ALNY) was one of the most underperforming biotech stocks for the week ended June 10, 2016. It fell 10% due to profit booking.
Why Is Acadia Pharmaceuticals Falling Today?
Yesterday, Acadia Pharmaceuticals reported top-line results from its phase three trial evaluating Nuplazid in schizophrenia.
Spectrum Pharmaceuticals: Earnings Trends and Recent Developments
In the first nine months of 2018, Spectrum Pharmaceuticals reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively.
Spectrum Pharmaceuticals: Financial Overview in December
In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY to $79.9 million from $99.8 million.
Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday
On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.
Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.
Exploring Acadia Pharmaceuticals’ Promising Research Pipeline
Acadia Pharmaceuticals’ Nuplazid is commercialized in the US market for the treatment of hallucinations and delusions related to Parkinson’s disease psychosis.
Why Axovant Sciences Stock Rose in Week Ended June 8
On June 6, Axovant Sciences entered into an agreement to develop and sell Oxford BioMedica’s OXB-102 for the treatment of Parkinson’s disease.
Nuplazid for Long-Term Care: Revenue Driver for Acadia?
Acadia Pharmaceuticals (ACAD) plans to focus on long-term care (or LTC) facilities to boost Nuplazid’s adoption in the Parkinson’s disease (or PD) psychosis indication.
Nuplazid Sees Increasing Physician Intent to Prescribe in 2017
Acadia Pharmaceuticals’ (ACAD) commercial teams have been carrying out promotional efforts to create awareness for Nuplazid among physicians with the intent to have them prescribe the drug.
Nuplazid Expected to Become a Leading Central Nervous System Drug
On April 29, 2016, the FDA approved Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) as a first therapy for treating patients with Parkinson’s disease (or PD) psychosis.
What Analysts Recommend for Acadia Pharmaceuticals in September
Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”
Analyst Estimates for Ionis Pharmaceuticals’ 2016 Revenue
Analyst estimates show Ionis Pharmaceuticals’ 2016 revenue at $237 million. That’s a decline of more than 16% compared to $284 million for 2015.
Mid-Cap News: Intercept Rose on Accelerated Approval of Ocaliva
Intercept Pharmaceuticals (ICPT) rose 19.6% for the week ended April 8, 2016. It closed at $156.36 and was trading above its 20-day and 100-day moving averages
Incyte Continues Its Growth Spree in 2015
Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.
XBI Mid-Cap News: Look Who Took a Beating on March 23
Among the 18 mid-cap stocks that XBI holds in its portfolio, 17 declined and only one advanced on March 23. Mid-caps represent ~30% of XBI’s portfolio.
Dyax Traded above Its 100-Day Moving Average
Dyax (DYAX) gained 9.41% last week. The stock went up after Dyax presented at the Morgan Stanley global healthcare conference, which took place September 16-18 in New York.
Anacor Pharmaceuticals Outperforms the Market
Within IBB, stocks like Receptos and Celgene performed well. However, Anacor Pharmaceuticals outperformed everyone with an eye-catching 71.92% for the week ending July 17.